$ASTH
Astrana Health, Inc. Stock $asth

$asth Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000162828020015999 Filed on November 09, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q4
Revenue	$176.8M	$180.1M	$178.8M
YoY Change	-1.1%	15.42%	69.43%
Cost Of Revenue	$137.1M	$121.8M	$151.9M
YoY Change	-9.74%	-7.1%	91.31%
Gross Profit	$39.70M	$58.30M	$26.90M
YoY Change	47.58%	133.85%	3.46%
Gross Profit Margin	22.46%	32.37%	15.05%
Selling, General & Admin	$9.500M	$16.30M	$11.50M
YoY Change	-17.39%	106.33%	-27.22%
% of Gross Profit	23.93%	27.96%	42.75%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$4.350M	$4.670M	$4.960M
YoY Change	-12.3%	-5.09%	10.71%
% of Gross Profit	10.96%	8.01%	18.44%
Operating Expenses	$13.80M	$21.00M	$15.90M
YoY Change	-13.21%	-85.62%	-21.67%
Operating Profit	$25.88M	$37.36M	$10.93M
YoY Change	136.68%	271.11%	91.81%
Interest Expense	-$600.0K	$2.466M	-$10.70M
YoY Change	-94.39%	197.83%	98.15%
% of Operating Profit	-2.32%	6.6%	-97.87%
Other Income/Expense, Net	-$400.0K	-$1.181M	$200.0K
YoY Change	-300.0%	-127.12%	-60.0%
Pretax Income	$24.80M	$36.18M	$400.0K
YoY Change	6100.0%	150.85%	-113.79%
Income Tax	$11.90M	$10.75M	$1.700M
% Of Pretax Income	47.98%	29.72%	425.0%
Net Earnings	$10.06M	$16.71M	$6.727M
YoY Change	49.5%	351.21%	-317.0%
Net Earnings / Revenue	5.69%	9.28%	3.76%
Basic Earnings Per Share	$0.27	$0.46	$0.19
Diluted Earnings Per Share	$0.26	$0.45	$0.18
COMMON SHARES
Basic Shares Outstanding	54.27M shares	36.36M shares	34.89M shares
Diluted Shares Outstanding		37.55M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$261.2M	$284.4M	$219.7M
YoY Change	18.89%	22.85%	103.43%
Cash & Equivalents	$193.5M	$166.1M	$103.2M
Short-Term Investments	$67.70M	$118.3M	$116.5M
Other Short-Term Assets	$16.70M	$12.10M	$10.40M
YoY Change	60.58%	15.24%	23.81%
Inventory
Prepaid Expenses
Receivables	$7.058M	$18.26M	$11.00M
Other Receivables	$4.297M	$3.988M	$16.89M
Total Short-Term Assets	$338.6M	$366.7M	$329.1M
YoY Change	2.89%	14.11%	90.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$48.50M	$30.20M	$26.40M
YoY Change	83.71%	143.02%	107.53%
Goodwill	$239.1M	$239.1M	$238.5M
YoY Change	0.23%	0.81%	28.36%
Intangibles	$86.99M	$90.78M	$103.0M
YoY Change	-15.56%	-20.48%	18.57%
Long-Term Investments	$43.29M	$27.22M	$28.43M
YoY Change	52.29%	-24.05%	-18.49%
Other Assets	$18.92M	$22.47M	$1.681M
YoY Change	1025.22%	1276.05%	39.39%
Total Long-Term Assets	$478.9M	$447.6M	$399.6M
YoY Change	19.83%	4.36%	17.5%
TOTAL ASSETS
Total Short-Term Assets	$338.6M	$366.7M	$329.1M
Total Long-Term Assets	$478.9M	$447.6M	$399.6M
Total Assets	$817.5M	$814.3M	$728.7M
YoY Change	12.18%	8.53%	42.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.554M	$9.569M	$6.914M
YoY Change	38.18%	119.82%	54.28%
Accrued Expenses	$10.10M	$13.50M	$6.200M
YoY Change	62.9%	84.93%	24.0%
Deferred Revenue	$12.99M	$12.25M	$8.892M
YoY Change	46.06%	-27.84%	-1.47%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.89M	$9.500M	$9.500M
YoY Change	14.62%	0.0%
Total Short-Term Liabilities	$115.0M	$131.5M	$105.4M
YoY Change	9.08%	24.97%	46.38%
LONG-TERM LIABILITIES
Long-Term Debt	$230.2M	$226.1M	$232.2M
YoY Change	-0.84%	-3.46%
Other Long-Term Liabilities	$0.00	$16.60M	$11.40M
YoY Change	-100.0%	39.5%	850.0%
Total Long-Term Liabilities	$257.3M	$254.7M	$262.2M
YoY Change	-1.86%	-7.95%	664.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$115.0M	$131.5M	$105.4M
Total Long-Term Liabilities	$257.3M	$254.7M	$262.2M
Total Liabilities	$372.3M	$386.1M	$367.7M
YoY Change	1.27%	1.12%	245.74%
SHAREHOLDERS EQUITY
Retained Earnings	$69.77M	$59.71M	$31.91M
YoY Change	118.68%	137.17%	79.36%
Common Stock	$42.00K	$37.00K	$36.00K
YoY Change	16.67%	6.25%	4.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$330.8M	$228.4M	$191.5M
YoY Change
Total Liabilities & Shareholders Equity	$817.5M	$814.3M	$728.7M
YoY Change	12.18%	8.53%	42.05%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q4
OPERATING ACTIVITIES
Net Income	$10.06M	$16.71M	$6.727M
YoY Change	49.5%	351.21%	-317.0%
Depreciation, Depletion And Amortization	$4.350M	$4.670M	$4.960M
YoY Change	-12.3%	-5.09%	10.71%
Cash From Operating Activities	-$2.600M	$36.18M	$3.590M
YoY Change	-172.42%	12.71%	-156.45%
INVESTING ACTIVITIES
Capital Expenditures	-$610.0K	-$100.0K	-$230.0K
YoY Change	165.22%	-76.74%	-23.33%
Acquisitions
YoY Change
Other Investing Activities	$29.71M	-$650.0K	-$120.0M
YoY Change	-124.75%	-93.29%	2492.44%
Cash From Investing Activities	$29.09M	-$750.0K	-$120.3M
YoY Change	-124.19%	-92.58%	2339.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	640.0K	-21.79M	-10.38M
YoY Change	-106.17%	-114.33%	78.66%
NET CHANGE
Cash From Operating Activities	-2.600M	36.18M	3.590M
Cash From Investing Activities	29.09M	-750.0K	-120.3M
Cash From Financing Activities	640.0K	-21.79M	-10.38M
Net Change In Cash	27.13M	13.64M	-127.1M
YoY Change	-121.35%	-92.16%	643.04%
FREE CASH FLOW
Cash From Operating Activities	-$2.600M	$36.18M	$3.590M
Capital Expenditures	-$610.0K	-$100.0K	-$230.0K
Free Cash Flow	-$1.990M	$36.28M	$3.820M
YoY Change	-152.09%	11.53%	-163.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001083446
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37392
	dei	Entity Registrant Name EntityRegistrantName	Apollo Medical Holdings, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4472349
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1668 S. Garfield Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	2nd Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Alhambra
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91801
	dei	City Area Code CityAreaCode	626
	dei	Local Phone Number LocalPhoneNumber	282-0288
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	AMEH
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54265602	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166082000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103189000	USD
CY2020Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	75000	USD
CY2020Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	118309000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	116539000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18257000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11004000	USD
CY2020Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	41518000	USD
CY2019Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	48136000	USD
CY2020Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3988000	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	16885000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12119000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10315000	USD
CY2020Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	6425000	USD
CY2019Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	6425000	USD
CY2020Q3	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	0	USD
CY2019Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	16500000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	366698000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	329068000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	746000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	746000	USD
CY2020Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10929000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	12130000	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	90781000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	103012000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	239053000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	238505000	USD
CY2020Q3	us-gaap	Equity Method Investments EquityMethodInvestments	27220000	USD
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	28427000	USD
CY2020Q3	ameh	Investment In Privately Held Entity That Does Not Report Net Asset Value InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue	37075000	USD
CY2019Q4	ameh	Investment In Privately Held Entity That Does Not Report Net Asset Value InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue	896000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19298000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14248000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22473000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1681000	USD
CY2020Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	447575000	USD
CY2019Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	399645000	USD
CY2020Q3	us-gaap	Assets Assets	814273000	USD
CY2019Q4	us-gaap	Assets Assets	728713000	USD
CY2020Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	40474000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	27279000	USD
CY2020Q3	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	3986000	USD
CY2019Q4	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	2027000	USD
CY2020Q3	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	57455000	USD
CY2019Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	58725000	USD
CY2020Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	16169000	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4529000	USD
CY2020Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	485000	USD
CY2019Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	271000	USD
CY2020Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	102000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	102000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3290000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2990000	USD
CY2020Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	9500000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9500000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	131461000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	105423000	USD
CY2020Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	11659000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	18269000	USD
CY2020Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	337000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	416000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16616000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11373000	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	226051000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	232172000	USD
CY2020Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	254663000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	262230000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	386124000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	367653000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	168725000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	198731000	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36775817	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35908057	shares
CY2020Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	17475707	shares
CY2019Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	17458810	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	168653000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	159608000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	59714000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	31905000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	229418000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	228404000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	191549000	USD
CY2020Q3	us-gaap	Minority Interest MinorityInterest	1014000	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	786000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	192335000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	814273000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	728713000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	180123000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	156060000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	510397000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	381867000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	121823000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	131130000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	402106000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	315925000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16270000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7950000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39660000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30031000	USD
CY2020Q3	ameh	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	4674000	USD
	ameh	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	14004000	USD
CY2019Q3	ameh	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	4920000	USD
	ameh	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	13793000	USD
CY2020Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1994000	USD
CY2019Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1363000	USD
CY2020Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1994000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	142767000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	145994000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	455770000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	360380000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	37356000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	10066000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	54627000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	21487000	USD
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	403000	USD
CY2019Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2054000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3291000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1162000	USD
CY2020Q3	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	USD
CY2019Q3	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	USD
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	99647000	USD
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	2466000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	828000	USD
	us-gaap	Interest Expense InterestExpense	8007000	USD
	us-gaap	Interest Expense InterestExpense	1350000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	752000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	509000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2544000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1305000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	130000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2620000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1514000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2832000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1181000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4355000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	98989000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3949000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	36175000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	14421000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	153616000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	25436000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10751000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3682000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44204000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6483000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	25424000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	10739000	USD
	us-gaap	Profit Loss ProfitLoss	109412000	USD
	us-gaap	Profit Loss ProfitLoss	18953000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	8711000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	7035000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	81603000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	11564000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	16713000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	3704000	USD
	us-gaap	Net Income Loss NetIncomeLoss	27809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	7389000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.75
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.20
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	192335000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1058000	USD
CY2020Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	0	USD
CY2020Q1	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	4147000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	301000	USD
CY2020Q1	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0	USD
CY2020Q1	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	722000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	197961000	USD
CY2020Q2	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	7335000	USD
CY2020Q2	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q2	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	2283000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	852000	USD
CY2020Q2	ameh	Stock Issued During Period Value Restricted Stock Award Cancelled StockIssuedDuringPeriodValueRestrictedStockAwardCancelled	236000	USD
CY2020Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	347000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	207848000	USD
CY2020Q3	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	16902000	USD
CY2020Q3	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0	USD
CY2020Q3	ameh	Stock Issued During Period Value Cashless Warrants Exercised StockIssuedDuringPeriodValueCashlessWarrantsExercised	0	USD
CY2020Q3	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	4020000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	648000	USD
CY2020Q3	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	0	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	229418000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	181544000	USD
CY2019Q1	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	550000	USD
CY2019Q1	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	0	USD
CY2019Q1	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	140000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	143000	USD
CY2019Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	0	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	182377000	USD
CY2019Q2	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	3768000	USD
CY2019Q2	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	758000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	128000	USD
CY2019Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	942000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	186089000	USD
CY2019Q3	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	4455000	USD
CY2019Q3	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	1502000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	128000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	0	USD
CY2019Q3	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	0	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	192174000	USD
	us-gaap	Profit Loss ProfitLoss	109412000	USD
	us-gaap	Profit Loss ProfitLoss	18953000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14004000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13793000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6953000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1904000	USD
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-6618000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1994000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1004000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1363000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2558000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1006000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-23000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	6000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3291000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1162000	USD
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	99647000	USD
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	USD
	ameh	Gain Loss On Assumption Of Loan GainLossOnAssumptionOfLoan	0	USD
	ameh	Gain Loss On Assumption Of Loan GainLossOnAssumptionOfLoan	2250000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-6137000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-186000	USD
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-5864000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-12898000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	13719000	USD
	ameh	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	1804000	USD
	ameh	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	2914000	USD
	ameh	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	2601000	USD
	ameh	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	1877000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5090000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	525000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12644000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4868000	USD
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	1958000	USD
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	196000	USD
	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	-1566000	USD
	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	-6226000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	11642000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-10229000	USD
	ameh	Increase Decrease In Other Operating Lease Liabilities IncreaseDecreaseInOtherOperatingLeaseLiabilities	-2110000	USD
	ameh	Increase Decrease In Other Operating Lease Liabilities IncreaseDecreaseInOtherOperatingLeaseLiabilities	-1790000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	48764000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10085000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	49403000	USD
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	16500000	USD
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	0	USD
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	0	USD
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	7425000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1793000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	500000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	2949000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	52743000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	553000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	807000	USD
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	60670000	USD
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	240000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	66397000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60364000	USD
	ameh	Repayments Of Bank Loan And Lines Of Credit RepaymentsOfBankLoanAndLinesOfCredit	0	USD
	ameh	Repayments Of Bank Loan And Lines Of Credit RepaymentsOfBankLoanAndLinesOfCredit	52640000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	50133000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7125000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	78000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	76000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6552000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2400000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1559000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	40000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	289600000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	755000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	5622000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-52343000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	173707000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	62818000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	123428000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104010000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107637000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	166828000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231065000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	37900000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	17900000	USD
	us-gaap	Interest Paid Net InterestPaidNet	6961000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1000000	USD
CY2020Q3	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	485000	USD
CY2019Q3	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	271000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103189000	USD
	ameh	Deferred Tax Liabilities Adjusted To Goodwill DeferredTaxLiabilitiesAdjustedToGoodwill	0	USD
	ameh	Deferred Tax Liabilities Adjusted To Goodwill DeferredTaxLiabilitiesAdjustedToGoodwill	11540000	USD
	ameh	Deferred Tax Liabilities Warrants Exercised DeferredTaxLiabilitiesWarrantsExercised	473000	USD
	ameh	Deferred Tax Liabilities Warrants Exercised DeferredTaxLiabilitiesWarrantsExercised	0	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	414000	USD
	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	36179000	USD
	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	0	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106892000	USD
CY2019Q4	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	75000	USD
CY2018Q4	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	0	USD
CY2019Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	746000	USD
CY2018Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	745000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104010000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107637000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166082000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230299000	USD
CY2020Q3	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	0	USD
CY2019Q3	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	20000	USD
CY2020Q3	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	746000	USD
CY2019Q3	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	746000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	166828000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231065000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. ("ApolloMed") together with its affiliated physician groups and consolidated entities (collectively, the “Company”) is a leading physician-centric, technology-enabled healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed's subsidiaries include management services organizations ("MSOs"), affiliated independent practice associations ("IPAs") and a Next Generation Accountable Care Organization ("NGACO"). Network Medical Management, Inc. ("NMM") and Apollo Medical Management, Inc. ("AMM") are the administrative and managerial services companies for the affiliated physician owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA ("APC"), Alpha Care Medical Group, Inc. and Accountable Health Care IPA brands. These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation ("AMH") and Southern California Heart Centers, a Medical Corporation ("SCHC"). The Company's NGACO operates under the APA ACO, Inc. ("APAACO") brand and participates in the Centers for Medicare & Medicaid Services program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program's attribution-based risk sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company’s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly-owned subsidiary of ApolloMed in December 2017. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC was incorporated in 1992, for the purpose of arranging healthcare services as an IPA. APC has contracts with various health maintenance organizations (“HMOs”) and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity (“VIE”) of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC’s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (“AP-AMH”) was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the rights to receive benefits from the operations of AP-AMH and has the option, but not the obligation, to cover losses. Therefore, AP-AMH is controlled and consolidated by ApolloMed as the primary beneficiary of this VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the “AP-AMH Loan”). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the “Certificate of Determination”), AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (i) APC’s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC’s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">APC purchased 15,015,015 shares of ApolloMed’s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed’s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed’s then outstanding shares will be voted by proxy given to ApolloMed’s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed’s stockholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the series of transaction, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term excluded assets ("Excluded Assets"). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company’s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii) and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC's ownership in ApolloMed was 32.00% at September 30, 2020 and 32.50% at December 31, 2019. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed in March 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of September 30, 2020, APC owned 45.01% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC’s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (“APC-LSMA”) was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group (“DMG”) and AHMC International Cancer Center, a Medical Corporation (“ICC”). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inc. (“MMG”), Alpha Care Medical Group, Inc. (“Alpha Care”), Accountable Health Care IPA, a Professional Medical Corporation (“Accountable Health Care”), and AMG, a Professional Medical Corporation (“AMG”). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care currently has a network of over 300 primary care physicians and 600 specialty care physicians, as well as one community and regional hospital medical center, that provides quality healthcare services to its members of three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care’s capital stock that they did not already own (comprising 75%) for $7.3 million in cash (see Note 3).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock (see Note 3).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Universal Care Acquisition Partners, LLC (“UCAP”), a 100% owned subsidiary of APC, was formed in June 2014, for the purpose of holding an investment in Universal Care, Inc. (“UCI”). On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright Health Company of California, Inc. ("Bright") for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.'s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was $15.7 million (see Note 5). As set forth in the Company’s definitive proxy statement filed with the SEC on July 31, 2019 (the “Proxy Statement”), the 48.9% interest in UCI is included in Excluded Assets that remain solely for the benefit of APC and its shareholders. As such, any proceeds or gain on the sale of APC’s indirect ownership interest in UCI has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the Proxy Statement and consequently the sale did not affect net income attributable to ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO, jointly owned by NMM and AMM, began participating in the Next Generation Accountable Care Organization (“NGACO") Model of the Centers for Medicare & Medicaid Services (“CMS”) in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. </span></div>AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (“AMH”) and Southern California Heart Centers, a Medical Corporation (“SCHC”). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing.
	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (“MLR”)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	321200000	USD
CY2020Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	118300000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	116500000	USD
	ameh	Risk Pool Surplus Or Deficits Settlement Period After Performance Year RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear	P18M
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1300000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2900000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentrations of RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	180123000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	156060000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	510397000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	381867000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	115039000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	118262000	USD
CY2020Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	47000	USD
CY2020Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	233348000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	50731000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	116469000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	70000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	167270000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	3	unit
CY2020Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2020Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	2000000.0	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	2000000.0	USD
	ameh	Risk Pool Settlement RiskPoolSettlement	19800000	USD
CY2020Q3	ameh	Risk Pool Settlement RiskPoolSettlement	19800000	USD
	ameh	Payment Of Revenue Monthly Amount PaymentOfRevenueMonthlyAmount	7600000	USD
CY2020Q3	ameh	Payment Of Revenue PaymentOfRevenue	22900000	USD
	ameh	Payment Of Revenue PaymentOfRevenue	68400000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	14800000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	57300000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12300000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8900000	USD
	ameh	Contract With Customer Liability Repaid Capitation Received And Not Earned ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned	8500000	USD
CY2020Q1	ameh	Investment Deposit InvestmentDeposit	4000000.0	USD
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.50
CY2019Q4	us-gaap	Goodwill Goodwill	238505000	USD
	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	548000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	239053000	USD
CY2020Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	176529000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	85748000	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	90781000	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	176529000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	73517000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	103012000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4000000.0	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12100000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3798000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	14524000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	12673000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	10842000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9830000	USD
CY2020Q3	ameh	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	39114000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	90781000	USD
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	28427000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3291000	USD
	ameh	Equity Method Investments Contribution EquityMethodInvestmentsContribution	500000	USD
	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	4998000	USD
CY2020Q3	us-gaap	Equity Method Investments EquityMethodInvestments	27220000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2481000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9569000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6914000	USD
CY2020Q3	ameh	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	2583000	USD
CY2019Q4	ameh	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	2813000	USD
CY2020Q3	ameh	Subcontractor Ipa Payable SubcontractorIPAPayable	3413000	USD
CY2019Q4	ameh	Subcontractor Ipa Payable SubcontractorIPAPayable	3360000	USD
CY2019Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	58725000	USD
CY2018Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	33642000	USD
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	229194000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8892000	USD
CY2020Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	40474000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1837000	USD
CY2020Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	225000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10176000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3238000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12252000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	27279000	USD
	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,642 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,473 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,744)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,455 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,820 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	175598000	USD
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	1731000	USD
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	2875000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	230925000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	178473000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	178796000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	135580000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	53231000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	49164000	USD
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	232027000	USD
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	184744000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	0	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	26404000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	-168000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	45000	USD
CY2020Q3	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	57455000	USD
CY2019Q3	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	53820000	USD
CY2020Q3	us-gaap	Line Of Credit LineOfCredit	240500000	USD
CY2020Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	9500000	USD
CY2020Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4949000	USD
CY2020Q3	us-gaap	Long Term Debt LongTermDebt	226051000	USD
CY2020Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2375000	USD
CY2020Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	10688000	USD
CY2020Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	14250000	USD
CY2020Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	15437000	USD
CY2020Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	197750000	USD
CY2020Q3	us-gaap	Line Of Credit LineOfCredit	240500000	USD
	ameh	Stock Issued During Period Shares Merger StockIssuedDuringPeriodSharesMerger	302732	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.91
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y5M12D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3300000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5600000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	11742	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	18.41
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	607346	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.22
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y5M1D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	120000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.58
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1800000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12228	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.57
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	486860	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.86
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	405833	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y9M
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3500000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	120000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	203524	shares
	ameh	Share Based Compensation Arrangement By Share Based Payment Award Cashless Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod	0	shares
	ameh	Share Based Compensation Arrangement By Share Based Payment Award Cashless Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod	0	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3154590	shares
CY2019Q4	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants	9.96
CY2019	ameh	Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm	P2Y3D
CY2019Q4	ameh	Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue	26700000	USD
	ameh	Number Of Warrants Granted NumberOfWarrantsGranted	0	shares
	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Grant In Period ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod	0
CY2020Q3	ameh	Class Of Warrants Or Right Grant In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue	0	USD
	ameh	Number Of Warrants Exercised NumberOfWarrantsExercised	800709	shares
	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Exercised In Period ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod	9.22
CY2020Q3	ameh	Class Of Warrants Or Right Exercises In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue	6000000	USD
	ameh	Class Of Warrant Or Right Cancelled In Period ClassOfWarrantOrRightCancelledInPeriod	0	shares
	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Forfeited In Period ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod	0
CY2020Q3	ameh	Class Of Warrants Or Right Forfeitures In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue	0	USD
CY2020Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2353881	shares
CY2020Q3	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants	10.21
	ameh	Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm	P1Y7M13D
CY2020Q3	ameh	Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue	18200000	USD
	ameh	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod	800709	shares
	ameh	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod	133221	shares
	ameh	Warrant Issued During Period Value Stock Options Exercised WarrantIssuedDuringPeriodValueStockOptionsExercised	6200000	USD
	ameh	Warrant Issued During Period Value Stock Options Exercised WarrantIssuedDuringPeriodValueStockOptionsExercised	1200000	USD
	ameh	Share Based Compensation Arrangement By Share Based Payment Award Warrants Cashless Exercise Provision Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod	127022	shares
	ameh	Stock Issued During Period Shares Cashless Warrants Exercised StockIssuedDuringPeriodSharesCashlessWarrantsExercised	66517	shares
	ameh	Percentage Of Financial Guarantee Benchmark Amount PercentageOfFinancialGuaranteeBenchmarkAmount	0.02
CY2018Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5000000.0	USD
CY2020Q3	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	5474000	USD
CY2019Q3	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	10979000	USD
	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	23081000	USD
	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	37858000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.288
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.255
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34643754	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37551740	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36364839	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37792266	shares
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36364839	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.75
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.20
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36149692	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34555124	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37249967	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37816698	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34643754	shares
CY2020Q3	ameh	Business Combination Shares Held Back To Secure Indemnification Percentage BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage	0.10
CY2019Q3	ameh	Business Combination Shares Held Back To Secure Indemnification Percentage BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage	0.10
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37551740	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37792266	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36149692	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34555124	shares
	ameh	Business Combination Shares Held Back To Secure Indemnification Percentage BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage	0.10
	ameh	Business Combination Shares Held Back To Secure Indemnification Percentage BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage	0.10
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37249967	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37816698	shares
CY2020Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2020Q3	us-gaap	Lessee Finance Lease Renewal Term1 LesseeFinanceLeaseRenewalTerm1	P10Y
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1784000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1489000	USD
	ameh	Lessee Operating Lease Termination Period If Applicable LesseeOperatingLeaseTerminationPeriodIfApplicable	P1Y
	ameh	Lessee Finance Lease Termination Period If Applicable LesseeFinanceLeaseTerminationPeriodIfApplicable	P1Y
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	400000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	500000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	300000	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	300000	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	26000	USD
CY2019Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	26000	USD
CY2020Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	USD
CY2019Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000	USD
CY2020Q3	us-gaap	Sublease Income SubleaseIncome	206000	USD
CY2019Q3	us-gaap	Sublease Income SubleaseIncome	103000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	1607000	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	1416000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	5172000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	13000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	3832000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	78000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	76000	USD
CY2020Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	26000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	11000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	13000	USD
	us-gaap	Sublease Income SubleaseIncome	567000	USD
	us-gaap	Sublease Income SubleaseIncome	309000	USD
	us-gaap	Lease Cost LeaseCost	4694000	USD
	us-gaap	Lease Cost LeaseCost	3612000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	1489000	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	1677000	USD
CY2020Q3	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	3000	USD
CY2019Q3	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000	USD
CY2019Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	26000	USD
CY2020Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	4369000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	3950000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	11000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y11M4D
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2020Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y11M1D
CY2019Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y11M1D
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0610
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0612
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	78000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	76000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7652000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	15417000	USD
CY2020Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0300
CY2019Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0300
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1173000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	30000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4297000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	119000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3529000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	119000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3303000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	119000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2940000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	79000	USD
CY2020Q3	ameh	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	9459000	USD
CY2020Q3	ameh	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24701000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	466000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4795000	USD
CY2020Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	27000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	19906000	USD
CY2020Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	439000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3290000	USD
CY2020Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	102000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16616000	USD
CY2020Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	337000	USD

Files In Submission

Name	View Source	Status
0001628280-20-015999-index-headers.html	Edgar Link	pending
0001628280-20-015999-index.html	Edgar Link	pending
0001628280-20-015999.txt	Edgar Link	pending
0001628280-20-015999-xbrl.zip	Edgar Link	pending
ameh-20200930.htm	Edgar Link	pending
ameh-20200930.xsd	Edgar Link	pending
ameh-20200930_cal.xml	Edgar Link	unprocessable
ameh-20200930_def.xml	Edgar Link	unprocessable
ameh-20200930_htm.xml	Edgar Link	completed
ameh-20200930_lab.xml	Edgar Link	unprocessable
ameh-20200930_pre.xml	Edgar Link	unprocessable
ex3112020093010-qng.htm	Edgar Link	pending
ex3122020093010-qng.htm	Edgar Link	pending
ex3132020093010-qng.htm	Edgar Link	pending
ex322020093010-qng.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASTH
Astrana Health, Inc. Stock $asth

2020 Q4 Form 10-Q Financial Statement

#000162828020015999 Filed on November 09, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH Astrana Health, Inc. Stock $asth

2020 Q4 Form 10-Q Financial Statement

#000162828020015999 Filed on November 09, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH
Astrana Health, Inc. Stock $asth